PD-L1, overexpressed on tumor cell surfaces, interacts with PD-1 on activated T cells, which causes cytotoxic T lymphocyte (CTL) dysfunction and T cell suppression, facilitating immune evasion and often correlates with poor clinical outcomes. The gene discussed is CD274; the disease is neoplasm.